IUSG
US Large Cap GrowthiShares Core S&P U.S. Growth ETF
iShares · Tracks S&P 900 Growth Index · Inception Jul 24, 2000
Composite score
Based on a 0.040% expense ratio.
Based on $32.22B in net assets.
Top-10 holdings represent 56.4% of net assets.
US Large Cap Growth base · ETF wrapper · 0.49% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use IUSG in our tools
Tool · Cost
Compare IUSG's fee against another fund
Compounds the 0.040% expense ratio against a peer over decades.
Tool · Overlap
Compare IUSG's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar US Large Cap Growth funds.
Tool · TLH
Find a tax-loss harvesting partner for IUSG
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | NVIDIA Corp. | 13.84% |
| 2 | Microsoft Corp. | 8.97% |
| 3 | Apple Inc. | 6.08% |
| 4 | Alphabet Inc. | 5.47% |
| 5 | Broadcom Inc | 4.79% |
| 6 | Alphabet Inc. | 4.38% |
| 7 | Meta Platforms Inc | 4.09% |
| 8 | Amazon.com, Inc. | 3.52% |
| 9 | Berkshire Hathaway Inc. | 2.87% |
| 10 | Eli Lilly & Co. | 2.38% |
Compare IUSG with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open IUSG at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.